NCT04510233.

Study name	Ivermectin nasal spray for COVID19 patients
Methods	Trial design: open‐label RCT with 3 parallel arms Type of record: trial register entry Sample size: 60 Setting: NR Country: Egypt Language: English Number of centres: NR Study purpose (treatment, prevention): treatment Trial registration number: NCT04510233 Date of registration: 12 August 2020
Participants	Inclusion criteria People of mild‐to‐moderate severity who are confirmed to be positive for SARS‐CoV‐2 Exclusion criteria People with severe form of COVID‐19 or those who are on ventilatory support or those with cytokine storm
Interventions	Details of intervention Type and dose Intervention 1: ivermectin nasal spray 1 mL in each nostril, twice daily Intervention 2: ivermectin 6 mg, 3 times daily for 3 days Route of administration: intranasal or oral Treatment details of control group No treatment except standard of care Concomitant therapy Standard of care including oxygen supplement administered in all study arms
Outcomes	Primary study outcome Negative PCR result of SARS‐Cov‐2 RNA in people with COVID‐19 at 14 days Relevant review outcomes planned Negative PCR result of SARS‐Cov‐2 RNA in people with COVID‐19 at 14 days Additional study outcomes None
Starting date	September 2020
Contact information	Kamal Okasha, PhD Tanta University Tanta 35111  Egypt okasha70@yahoo.com
Notes	Recruitment status: not yet recruiting Prospective completion date: October 2020 Date last update posted: 12 August 2020 Sponsor/funding: Tanta University